Role of Pemetrexed and Platinums Combination in Patients with Non- Small Cell Lung Cancer

E-ISSN： 1873-5592|11|1|29-36

ISSN： 1389-4501

Source： Current Drug Targets, Vol.11, Iss.1, 2010-01, pp. : 29-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The incidence of lung cancer in 2007 is estimated to be 213,380 with 160,390 deaths in the United States. It contributed to 31% of male and 26% of female cancer-related deaths and is the largest cause of cancer-related mortality in both men and women. Despite some advances in the treatment of advanced non-small cell lung cancer (NSCLC), the introduction of third-generation cytotoxic agents (vinorelbine, gemcitabine, docetaxel, irinotecan, and paclitaxel) has not achieved a breakthrough in the dismal prognosis of this disease. Several meta-analyses have proved the superiority of 2- drug chemotherapy and cisplatin-based chemotherapy, but no gold standard exists. This paper summarizes the clinical data of a new cytotoxic agent, pemetrexed, and its combination with platinums in the treatment of NSCLC. The addition of vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) or an EGFR-targeted drug (cetuximab) to pemetrexed/platinum in NSCLC, and the role of pemetrexed/platinum in adjuvant chemotherapy for early-stage NSCLC were also discussed in this paper.